C

Corvus Pharmaceuticals
D

CRVS

8.95000
USD
0.01
(0.11%)
مغلق
حجم التداول
44,812
الربح لكل سهم
-1
العائد الربحي
-
P/E
-9
حجم السوق
575,102,396
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ABUS
    0.01000
    (0.28%)
    3.64000 USD
    A
    ARWR
    -2.890
    (-13.49%)
    18.540 USD
    C
    CRSP
    0.360
    (0.77%)
    47.280 USD
    E
    EDIT
    -0.11500
    (-4.14%)
    2.66500 USD
    F
    FIXX
    0
    (0%)
    0.000000 USD
    N
    NVTA
    0
    (0%)
    0.000000 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    R
    RGNX
    -1.51500
    (-13.60%)
    9.62500 USD
    S
    SRPT
    -4.470
    (-4.10%)
    104.600 USD
    V
    VYGR
    -0.57000
    (-9.18%)
    5.64000 USD
    المزيد
الأخبار

العنوان: Corvus Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).